Delving into the Latest Updates on Suzhou Yasheng Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Hemic and Lymphatic Diseases

Immune System Diseases

Small molecule drug

Chemical drugs

Proteolysis-targeting chimeras (PROTAC)

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	12
Immune System Diseases	7
Hemic and Lymphatic Diseases	6
Endocrinology and Metabolic Disease	6
Nervous System Diseases	2
Infectious Diseases	2

Top 5 Drug Type	Count

Small molecule drug	10
Chemical drugs	1
Proteolysis-targeting chimeras (PROTAC)	1

Top 5 Target	Count

KRAS G12D(GTPase KRas G12D)	2
ALK x FAK x ROS1	1
XIAP x cIAP1/cIAP2	1
CK1α x GSPT1 x IKZF1 x IKZF2 x IKZF3 x N-Myc x c-Myc	1
Bcl-2(Apoptosis regulator Bcl-2)	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

4

1

Preclinical

Phase 1

2

3

Phase 2

NDA/BLA

1

Approved

Other

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Olverembatinib ( Bcr-Abl T315I x c-Kit )	Philadelphia positive acute lymphocytic leukaemia More	Phase 3
Lisaftoclax ( Bcl-2 )	Waldenstrom Macroglobulinemia More	Phase 2
Alrizomadlin ( MDM2 x p53 )	Diffuse Large B-Cell Lymphoma More	Phase 2
Dasminapant ( XIAP x cIAP1/cIAP2 )	Hepatitis B, Chronic More	Phase 2
APG-2449 ( ALK x FAK x ROS1 )	Advanced Malignant Solid Neoplasm More	Phase 1